{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:27:14Z","timestamp":1752550034598},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05801-0","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:02:07Z","timestamp":1718186527000},"page":"2787-2795","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib"],"prefix":"10.1007","volume":"103","author":[{"given":"Daniele","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia Anna","family":"Fidanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Artuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"5801_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B (2023) Myelofibrosis Blood 141:1954\u20131970","journal-title":"Myelofibrosis Blood"},{"key":"5801_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/archinte.1988.00380040062012","volume":"148","author":"DL Simel","year":"1988","unstructured":"Simel DL, DeLong ER, Feussner JR, Weinberg JB, Crawford J (1988) Erythrocyte anisocytosis. Visual inspection of blood films vs automated analysis of red blood cell distribution width. Arch Intern Med 148:822\u2013824","journal-title":"Arch Intern Med"},{"key":"5801_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacc.2007.02.067","volume":"50","author":"GM Felker","year":"2007","unstructured":"Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA et al (2007) Red cell distribution width as a novel prognostic marker in heart failure: data from the charm program and the duke databank. J Am Coll Cardiol 50:40\u201347","journal-title":"J Am Coll Cardiol"},{"key":"5801_CR4","first-page":"121","volume":"5","author":"C Seretis","year":"2013","unstructured":"Seretis C, Seretis F, Lagoudianakis E, Gemenetzis G, Salemis NS (2013) Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J Clin Med Res 5:121\u2013126","journal-title":"J Clin Med Res"},{"key":"5801_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3325\/cmj.2015.56.334","volume":"56","author":"V Perisa","year":"2015","unstructured":"Perisa V, Zibar L, Sincic-Petricevic J, Knezovic A, Perisa I, Barbic J (2015) Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. Croat Med J 56:334\u2013343","journal-title":"Croat Med J"},{"key":"5801_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cyto.2012.01.005","volume":"58","author":"D de Gonzalo-Calvo","year":"2012","unstructured":"de Gonzalo-Calvo D, de Luxan-Delgado B, Rodriguez-Gonzalez S, Garc\u00eda-Macia M, Su\u00e1rez FM, Solano JJ et al (2012) Interleukin 6, soluble tumor necrosis factor receptor i and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. Cytokine 58:193\u2013198","journal-title":"Cytokine"},{"key":"5801_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2011.02.057","volume":"58","author":"CJ Rhodes","year":"2011","unstructured":"Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS et al (2011) Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 58:300\u2013309","journal-title":"J Am Coll Cardiol"},{"key":"5801_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.5858\/133.4.628","volume":"133","author":"G Lippi","year":"2009","unstructured":"Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC (2009) Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med 133:628\u2013632","journal-title":"Arch Pathol Lab Med"},{"key":"5801_CR9","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.bcmd.2019.102368","volume":"80","author":"I Krecak","year":"2020","unstructured":"Krecak I, Krecak F, Gveric-Krecak V (2020) High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. Blood Cells Mol Dis 80:102368","journal-title":"Blood Cells Mol Dis"},{"key":"5801_CR10","doi-asserted-by":"publisher","first-page":"e2022058","DOI":"10.1001\/jamanetworkopen.2020.22058","volume":"3","author":"BH Foy","year":"2020","unstructured":"Foy BH, Carlson JCT, Reinertsen E, Padros I, Valls R, Pallares Lopez R et al (2020) Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open 3:e2022058","journal-title":"JAMA Netw Open"},{"key":"5801_CR11","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1002\/jmv.27785","volume":"94","author":"M Lucijanic","year":"2022","unstructured":"Lucijanic M, Soric E, Sedinic Lacko M, Sabljic A, Krecak I, Bistrovic P et al (2022) Gradual increase in red cell distribution width is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients. J Med Virol 94:3509\u20133511","journal-title":"J Med Virol"},{"key":"5801_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41375-021-01410-2","volume":"36","author":"D Liu","year":"2022","unstructured":"Liu D, Li B, Xu Z, Zhang P, Qin T, Qu S et al (2022) RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia 36:566\u2013568","journal-title":"Leukemia"},{"key":"5801_CR13","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kre\u010dak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW et al (2023) Identifying patients with Polycythemia Vera at risk of thrombosis after Hydroxyurea initiation: the Polycythemia Vera-Advanced Integrated models (PV-AIM) Project. Biomedicines 11:1925.","DOI":"10.3390\/biomedicines11071925"},{"key":"5801_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000445247","volume":"136","author":"M Lucijanic","year":"2016","unstructured":"Lucijanic M, Pejsa V, Jaksic O, Mitrovic Z, Tomasovic-Loncaric C, Stoos-Veic T et al (2016) The degree of Anisocytosis predicts survival in patients with primary myelofibrosis. Acta Haematol 136:98\u2013100","journal-title":"Acta Haematol"},{"key":"5801_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00277-021-04724-4","volume":"101","author":"M Lucijanic","year":"2022","unstructured":"Lucijanic M, Krecak I, Verstovsek S, Soric E, Galusic D, Holik H et al (2022) Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis. Ann Hematol 101:1355\u20131357","journal-title":"Ann Hematol"},{"key":"5801_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36:1703\u20131719","journal-title":"Leukemia"},{"key":"5801_CR17","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228","journal-title":"Blood"},{"key":"5801_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 22:437\u2013438","journal-title":"Leukemia"},{"key":"5801_CR19","first-page":"127","volume-title":"WHO classification of Tumours of Haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris L et al (2008) WHO classification of Tumours of Haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 127\u2013129","edition":"4"},{"key":"5801_CR20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703\u20131708","journal-title":"Blood"},{"key":"5801_CR21","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M et al (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31:2726\u20132731","journal-title":"Leukemia"},{"key":"5801_CR22","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20132901","journal-title":"Blood"},{"key":"5801_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"5801_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2013.219","volume":"27","author":"JV Jovanovic","year":"2013","unstructured":"Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B et al (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:2032\u20132039","journal-title":"Leukemia"},{"key":"5801_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405","journal-title":"N Engl J Med"},{"key":"5801_CR26","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","volume":"33","author":"KA Rack","year":"2019","unstructured":"Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B et al (2019) European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia 33:1851\u20131867","journal-title":"Leukemia"},{"key":"5801_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397","journal-title":"J Clin Oncol"},{"key":"5801_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC et al (2022) A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 6:1855\u20131864","journal-title":"Blood Adv"},{"key":"5801_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M et al (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36:310\u2013318","journal-title":"J Clin Oncol"},{"key":"5801_CR30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","volume":"213","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S et al (2016) Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213:1723\u20131740","journal-title":"J Exp Med"},{"key":"5801_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W et al (2007) Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110:986\u2013993","journal-title":"Blood"},{"key":"5801_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A (2023) Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:801\u2013821","journal-title":"Am J Hematol"},{"key":"5801_CR33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","volume":"1","author":"L Naymagon","year":"2017","unstructured":"Naymagon L, Mascarenhas J (2017) Myelofibrosis-related anemia: current and emerging therapeutic strategies. HemaSphere 1:e1","journal-title":"HemaSphere"},{"key":"5801_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ejh.13198","volume":"102","author":"G Birgegard","year":"2019","unstructured":"Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W et al (2019) Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the nordic MPN study Group. Eur J Haematol 102:235\u2013240","journal-title":"Eur J Haematol"},{"key":"5801_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bjh.18526","volume":"200","author":"A Iurlo","year":"2023","unstructured":"Iurlo A, Galli N, Bucelli C, Artuso S, Consonni D, Cattaneo D (2023) Trend of circulating CD34\u2009+\u2009cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. Br J Haematol 200:315\u2013322","journal-title":"Br J Haematol"},{"key":"5801_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajh.24572","volume":"92","author":"N Polverelli","year":"2017","unstructured":"Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R et al (2017) Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol 92:37\u201341","journal-title":"Am J Hematol"},{"key":"5801_CR37","doi-asserted-by":"publisher","first-page":"750346","DOI":"10.3389\/fimmu.2021.750346","volume":"12","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Iurlo A (2021) Immune Dysregulation and Infectious complications in MPN patients treated with JAK inhibitors. Front Immunol 12:750346","journal-title":"Front Immunol"},{"key":"5801_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G et al (2020) Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 126:1243\u20131252","journal-title":"Cancer"},{"key":"5801_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT et al (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401:269\u2013280","journal-title":"Lancet"},{"key":"5801_CR40","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A et al (2017) SIMPLIFY-1: a phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus kinase Inhibitor-Na\u00efve patients with myelofibrosis. J Clin Oncol 35:3844\u20133850","journal-title":"J Clin Oncol"},{"key":"5801_CR41","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D et al (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5:e73\u2013e81","journal-title":"Lancet Haematol"},{"key":"5801_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/ajh.27163","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Pardanani A, Gangat N (2024) Momelotinib expands the therapeutic armamentarium for myelofibrosis: impact on hierarchy of treatment choices. Am J Hematol 99:300\u2013308","journal-title":"Am J Hematol"},{"key":"5801_CR43","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","volume":"7","author":"ST Oh","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V et al (2023) Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 7:5835\u20135842","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05801-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T03:34:01Z","timestamp":1726716841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5801"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05801-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the authors declare they have no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}